Literature DB >> 16343361

Treatment of neuro-ophthalmologic manifestations of tuberculosis.

Susannah Mistr1, Pamela S Chavis.   

Abstract

In the absence of obvious pulmonary or disseminated tuberculosis, ocular and central nervous system (CNS) tuberculosis may represent a significant diagnostic challenge. Refinements in polymerase chain reaction techniques and neuroimaging have strengthened the battery of tests used to diagnose CNS and ocular tuberculosis, yet in many cases, the diagnosis remains one of exclusion; it may ultimately be determined through exacerbation by anti-inflammatory therapy with subsequent improvement by antitubercular medication treatment. Because of emerging drug resistance, at least a two-drug regimen is required for therapeutic testing and treatment of isolated ocular tuberculosis. If pulmonary or miliary disease coexists, a 6-month, four-drug regimen with isoniazid, rifampin, pyrazinamide, and ethambutol is required for treatment. Tubercular meningitis is treated with the same four-drug regimen for at least 9 to 12 months. Burden of therapeutic compliance rests on the treating physician and public health sector. Best compliance is realized with directly observed therapy.

Entities:  

Year:  2006        PMID: 16343361     DOI: 10.1007/s11940-996-0024-8

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  108 in total

1.  Rapid improvement of intracranial tuberculomas after addition of ofloxacin to first-line antituberculosis treatment.

Authors:  I Sermet-Gaudelus; F Stambouli; V Abadie; F Goutières; G Lenoir; D Gendrel; J L Gaillard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-10       Impact factor: 3.267

2.  Unilateral tuberculous conjunctivitis with tarsal necrosis.

Authors:  Merle Fernandes; Geeta K Vemuganti; Gunisha Pasricha; Aashish K Bansal; Virender S Sangwan
Journal:  Arch Ophthalmol       Date:  2003-10

3.  Ocular tuberculosis.

Authors:  C D Regillo; C L Shields; J A Shields; R C Eagle; J Lehr
Journal:  JAMA       Date:  1991-09-18       Impact factor: 56.272

Review 4.  Optochiasmatic tuberculoma--case report and review.

Authors:  H H Kadioglu; C Gundogdu; O Deniz; E Takçi; Y Tüzün; I H Aydin
Journal:  Zentralbl Neurochir       Date:  1996

5.  A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection.

Authors:  P A Selwyn; D Hartel; V A Lewis; E E Schoenbaum; S H Vermund; R S Klein; A T Walker; G H Friedland
Journal:  N Engl J Med       Date:  1989-03-02       Impact factor: 91.245

6.  The management of mycobacterial infection--a UK survey.

Authors:  A M Lovering; L O White; C Acaye; D S Reeves; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  1995-10       Impact factor: 5.790

7.  Evaluation of lymphocyte proliferation assay to purified protein derivative, enzyme linked immunosorbant assay, and tuberculin hypersensitivity in Eales' disease.

Authors:  J Biswas; S Narain; S Roy; H N Madhavan
Journal:  Indian J Ophthalmol       Date:  1997-06       Impact factor: 1.848

8.  Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country.

Authors:  Young Ae Kang; Hye Won Lee; Ho Il Yoon; BeLong Cho; Sung Koo Han; Young-Soo Shim; Jae-Joon Yim
Journal:  JAMA       Date:  2005-06-08       Impact factor: 56.272

9.  Prognosis of tuberculous meningitis in adults in the era of modern antituberculous chemotherapy.

Authors:  Jann-Tay Wang; Chien-Ching Hung; Wang-Huei Sheng; Jann-Yuan Wang; Shan-Chwen Chang; Kwen-Tay Luh
Journal:  J Microbiol Immunol Infect       Date:  2002-12       Impact factor: 4.399

10.  Iris nodules associated with infectious uveitis.

Authors:  T D Myers; J R Smith; A K Lauer; J T Rosenbaum
Journal:  Br J Ophthalmol       Date:  2002-09       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.